No. |
Title |
Author |
Journal |
Vol&Page |
Year |
Pub Med ID |
1 |
Clinical benefit of non-toxic therapy in patients with advanced cancer (opinion). |
Goto S, Shirotani N, Hatakeyama M, Tagami C, Arakawa H, Kuwata E, Noguchi K, Egawa K. |
Anticancer Res. |
22(4):2461-4. |
2002 |
|
2 |
肺癌術後局所再発および転移性肺腫瘍し対する局所療法 |
馬場雅行、山口 豊、藤沢武彦ら |
癌と化学療法 |
15(4): 1342-1350 |
1988 |
|
3 |
Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers. |
Komatsu T, Yamauchi K, Furukawa T, Obata H. |
J Clin Immunol |
10(3):167-74. |
1990 |
|
4 |
固層化CD3抗体により活性化したT Cell(CD3-LAK)を用いた養子免疫療法 |
関根暉彬 |
Biotherapy |
4(10): 1606-1613 |
1990 |
|
5 |
腎細胞癌患者の養子免疫療法に関する研究 第２編：進行性腎細胞癌に対する血漿交換併用LAK療法 |
薄井昭博 |
日本泌尿器科学会雑誌 |
81(7): 1058-1064 |
1990 |
|
6 |
LAK細胞養子免疫療法の現状と問題点 |
山口佳之、高山孝弘、川見弘之ら |
日本外科学会雑誌 |
92(9): 1234-1236 |
1991 |
|
7 |
進行腎癌に対するlymphokine-activated killer cellおよびinterleukin-2による併用療法の有用性ならびにその限界 |
中野悦次、岩崎 明、瀬口利信ら |
日本泌尿器科学会雑誌 |
82(3): 395-404 |
1991 |
|
8 |
Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. |
Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, Takahashi T. |
Cancer Res. |
51(7):1934-9 |
1991 |
|
9 |
進行腎癌に対するlymphokine-Activated Killer (LAK) 細胞とinterleukin-2による併用療法の研究 |
野村一雄、藤岡知昭 |
日本泌尿器科学会雑誌 |
84(5): 831-840 |
1993 |
|
10 |
Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients. |
Ibayashi Y, Yamaki T, Kawahara T, Daibo M, Kubota T, Uede T, Tanabe S, Hashi K.
|
Neurol Med Chir (Tokyo). |
33(7):448-57. |
1993 |
|
11 |
Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies. |
Kimoto Y, Tanaka T, Tanji Y, Fujiwara A, Taguchi T.
|
Biotherapy. |
8(1):41-50. |
1994 |
|
12 |
進行卵巣癌に対する活性化T Cell（CD3-AT)を用いた養子免疫療法の治療効果 |
竹田省 |
J. Jpn. Soc. Ther. |
30(7): 967-971 |
1995 |
|
13 |
Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy. |
Haruta I, Yamauchi K, Aruga A, Komatsu T, Takasaki K, Hayashi N, Hanyu F.
|
J Immunother Emphasis Tumor Immunol. |
19(3):218-23. |
1996 |
|
14 |
Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. |
Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, Terunuma M, Nishiyama T, Takahashi K.
|
Int J Urol. |
5(1):16-21. |
1998 |
|
15 |
CTL療法 |
有賀淳、高崎 健 |
血液・腫瘍科 |
38(1): 45-52 |
1999 |
|
16 |
癌集学的治療における 体外 cell therapyの意義 |
山口佳之、大田耕司、峠哲哉 |
癌治療と宿主 |
12(2): 172-177 |
2000 |
|
17 |
癌特異的免疫療法−CTL療法の現状と将来 |
谷 眞至、谷村 弘、山上裕機 |
癌治療と宿主 |
12(4): 330-335 |
2000 |
|
18 |
Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels. |
Ebina T, Ogama N, Shimanuki H, Kubota T, Isono N. |
Cancer Immunol Immunother. |
52(9):555-60 |
2003 |
|
19 |
A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. |
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA, Simpson C. |
Surgery. |
100(2):262-72. |
1986 |
|
20 |
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. |
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. |
N Engl J Med. |
316(15):889-97. |
1987 |
|
21 |
Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. |
Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW 2nd, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE, et al. |
J Clin Oncol. |
8(10):1618-29. |
1990 |
|
22 |
Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. |
Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A. |
J Clin Oncol. |
10(6):960-8. |
1992 |
|
23 |
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. |
Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al. |
J Natl Cancer Inst. |
85(8):622-32. |
1993 |
|
24 |
Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. |
Aruga A, Yamauchi K, Takasaki K, Furukawa T, Hanyu F. |
Int J Cancer. |
49(1):19-24. |
1991 |
|
25 |
Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report. |
Takayama T, Makuuchi M, Sekine T, Terui S, Shiraiwa H, Kosuge T, Yamazaki S, Hasegawa H, Suzuki K, Yamagata M, et al. |
Cancer. |
68(11):2391-6. |
1991 |
|
26 |
Locoregional cellular immunotherapy for patients with advanced esophageal cancer. |
Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, Fujita H, Shirozou K, Itoh K. |
Clin Cancer Res. |
6(12):4663-73 |
2000 |
|
27 |
Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. |
Gomez GG, Hutchison RB, Kruse CA. |
Cancer Treat Rev. |
27(6):375-402. |
2001 |
|
28 |
Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. |
Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, Tanaka K. |
Clin Cancer Res. |
1(5):501-7. |
1995 |
|
29 |
A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. |
Kimura H, Yamaguchi Y. |
Cancer. |
80(1):42-9. |
1997 |
|
30 |
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. |
Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. |
Lancet. |
356(9232):802-7. |
2000 |
|
